Supervised Endurance Training Among Pulmonary Arterial Hypertension Patients
NCT ID: NCT05947032
Last Updated: 2024-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2023-08-20
2023-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparative Effects of Aerobic Exercises, Resistance Training and Combined Training on Heart Failure Patients
NCT04937231
Eccentric Resistance Training Among Individuals With Chronic Heart Failure
NCT06032780
High Intensity Aerobic Interval Training Versus Continuous Training in Heart Failure Patients.
NCT05948371
Structured Gym Activities and Aerobic Activities in People With Cardiac Conditions
NCT05059925
Effects of Exercise Program on Physical Functioning of Hemodialysis Patients.
NCT04674930
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Supervised endurance exercise training + Patient Education
Supervised endurance exercise training + Patient Education
ENDURANCE TRAINING:
Treadmill Walking:
Frequency: 15 to 20 sessions for 3 to 5 days per week. Intensity: 40% to 60% of HRR Time: 15 Min Type: aerobic training
Recumbent Bike:
Frequency: 15 to 20 sessions for 3 to 5 days/week. Intensity: 40% to 60% HRR Time: 15 Min Type: aerobic training
\+ Patient Education
Home exercises + Patient Education
Home exercises + Patient Education
HOME EXERCISES:
CONVENTIONAL Treatment:
Walking:
Frequency: 2 times/ day Intensity: as tolerated Time: 30 Min Type: aerobic training
Stair climbing:
Frequency: 1 flight/ day Type: aerobic training
\+ Patient Education
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Supervised endurance exercise training + Patient Education
ENDURANCE TRAINING:
Treadmill Walking:
Frequency: 15 to 20 sessions for 3 to 5 days per week. Intensity: 40% to 60% of HRR Time: 15 Min Type: aerobic training
Recumbent Bike:
Frequency: 15 to 20 sessions for 3 to 5 days/week. Intensity: 40% to 60% HRR Time: 15 Min Type: aerobic training
\+ Patient Education
Home exercises + Patient Education
HOME EXERCISES:
CONVENTIONAL Treatment:
Walking:
Frequency: 2 times/ day Intensity: as tolerated Time: 30 Min Type: aerobic training
Stair climbing:
Frequency: 1 flight/ day Type: aerobic training
\+ Patient Education
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age = 21 to 82
* Patients with documented PAH diagnosed by echocardiography (enlarged RA an enlarged RV with a thick wall, septal shift by enlarged chambers of right side of heart, an elevated mPAP) or a resting mean pulmonary arterial pressure equal to 25mm Hg determined by right heart catheterization.
* Patients on stable PH therapies, sedentary, and had no pulmonary rehabilitation for 6 months prior to enrolment.
Exclusion Criteria
* A documented pulmonary capillary wedge pressure greater then or equal to 15 mm Hg.
* Significant hepatic, renal, metabolic or mitochondrial dysfunctions; severe psychiatric disease; use of beta-adrenergic blockers or antiretroviral therapies; and any musculoskeletal or neurological condition that would limit walking or exercise performance.
* Patients with a history of heart failure.
20 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Riphah International University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Muhammad Iqbal Tariq, PhD*
Role: PRINCIPAL_INVESTIGATOR
Riphah International University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lady Reading hospital
Peshawar, Khyber Pakhtunkhwa, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REC/01603 Farheen Khan
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.